Amgen (NASDAQ:AMGN) has been given a $220.00 price target by stock analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the medical research company’s stock. Jefferies Financial Group’s price target points to a potential upside of 8.41% from the company’s previous close.

A number of other research firms have also commented on AMGN. Mizuho set a $200.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Tuesday, May 15th. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a research note on Friday, May 25th. TheStreet raised Amgen from a “c+” rating to a “b-” rating in a research note on Friday, May 25th. Cann reissued a “buy” rating on shares of Amgen in a research note on Friday, June 8th. Finally, Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $207.00 price objective on the stock in a research note on Tuesday, June 26th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $202.76.

Shares of AMGN stock opened at $202.93 on Wednesday. The company has a current ratio of 3.39, a quick ratio of 3.12 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $129.13 billion, a P/E ratio of 14.82, a P/E/G ratio of 1.94 and a beta of 1.39. Amgen has a one year low of $163.31 and a one year high of $203.69.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, July 26th. The medical research company reported $3.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.52 by $0.31. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. Amgen’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.27 EPS. research analysts expect that Amgen will post 13.95 earnings per share for the current fiscal year.

In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $195.71, for a total transaction of $298,457.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.19% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HRT Financial LLC increased its holdings in Amgen by 23.0% in the second quarter. HRT Financial LLC now owns 2,507 shares of the medical research company’s stock valued at $462,000 after purchasing an additional 469 shares during the last quarter. LFA Lugano Financial Advisors SA bought a new stake in shares of Amgen in the second quarter worth about $209,000. Mainstay Capital Management LLC ADV bought a new stake in shares of Amgen in the second quarter worth about $111,000. Advisors Asset Management Inc. increased its holdings in shares of Amgen by 1.0% in the second quarter. Advisors Asset Management Inc. now owns 69,408 shares of the medical research company’s stock worth $12,812,000 after acquiring an additional 719 shares in the last quarter. Finally, SRS Capital Advisors Inc. increased its holdings in shares of Amgen by 21.3% in the second quarter. SRS Capital Advisors Inc. now owns 2,391 shares of the medical research company’s stock worth $441,000 after acquiring an additional 420 shares in the last quarter. Institutional investors and hedge funds own 77.20% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: What is a Tariff?

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.